title: [Cost-effectiveness analysis on continuous subcutaneous insulin infusion and multi-point daily insulin injections in the treatment program of type 2 diabetes].
abstract: OBJECTIVE
  To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS II) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients.
  
  
  METHODS
  Retrospective analysis on 86 cases taking CS II and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs.
  
  
  RESULTS
  After two weeks of treatment, the effectiveness in the control of blood sugar in CS II group was similar to the MDI group, with no significant difference (P<0.05) and the adverse reactions were similar. Costs in the CS II program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS II group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS II group as a reference, the incremental cost-effectiveness ratio (DeltaC/DeltaE) of the MDI group was 129.20.
  
  
  CONCLUSIONS
  Costs-effective of the CS II program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS II program might be a better choice for hospitals to carry on an intensive insulin therapy program.
authors: Department of Endocrinology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors: Jiong
authors: J
authors: Shu
authors: Long-Yi
authors: LY
authors: Zeng
authors: Pan-Wei
authors: PW
authors: Mu
authors: Man-Man
authors: MM
authors: Wang
authors: Guo-Chao
authors: GC
authors: Zhang
authors: Yan-Ming
authors: YM
authors: Chen
mesh_terms: D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D004334:Drug Administration Schedule; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000191:economics; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000191:economics; D007332:Insulin Infusion Systems / Q000191:economics*; D015397:Program Evaluation; D012189:Retrospective Studies
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin